April 5, 2012
Amsterdam Molecular Therapeutics (AMT) Holding N.V. in liquidation (
) (Euronext: AMT), announces that following the approval of the corporate restructuring and financing transaction by the Extraordinary General Meeting ("
") of shareholders that was held on
30 March 2012
, completion of the disposal of AMT's entire business and operations to uniQure B.V. has taken place on
5 April 2012
. Immediately following the completion of the disposal and consequently as per
5 April 2012
, the dissolution of the company as resolved by the EGM has become effective, with Mr. Jörn Aldag and Mr.
being the liquidators that shall liquidate the company's dissolved property.
As consideration for the disposed business and operation, AMT received 31,101,065 depositary receipts (
certificaten van aandelen
) for (class B) ordinary shares in uniQure B.V. ("
"). Because AMT's dissolved property consists of the uniQure DRs without it having any known financial liabilities, and the financial condition is expected to justify the same, the liquidators of AMT intend to make an advance liquidation distribution (the "
") to the AMT shareholders by distributing and allocating to each such shareholder one uniQure DR for each AMT share held on the Distribution Record Date. The Distribution Record Date is expected to be
23 April 2012
and the date on which the Advance Distribution of the uniQure DRs is expected to take place is
26 April 2012
The Advance Distribution of the uniQure DRs to the AMT shareholders will be settled through the book entry system operated by Euroclear Netherlands, and will result in one uniQure DR being credited in the securities account of each AMT shareholder for each AMT share held on the Distribution Record Date. Consequently, to receive uniQure DRs, a person must hold AMT shares on the Distribution Record Date. To hold AMT shares on the Distribution Record Date, a shareholder must have bought such shares before the Ex Date, which shall be the second business day prior to the Distribution Record Date. Conversely, shareholders that do not want to receive uniQure DRs, must sell their AMT shares before the Ex Date. Shareholders having questions or requiring additional information on this settlement though Euroclear Netherlands are recommended to contact their bank or intermediary or other adviser.